Donor CAR-T cells for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia cells must have the CD117 marker on them.
- You must have relapsed or refractory AML, meaning it came back or didn't respond to standard treatments.
- At least 5% of the cells in your bone marrow must be leukemia blasts (immature cells).
- Your liver, heart, and kidney function must be within acceptable limits.
- You need to be in generally good health with a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.